Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE